Učitavanje...
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19
The recent pandemic of COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an extraordinary challenge to identify effective drugs for prevention and treatment. The pathogenesis implicate acute respiratory disorder (ARD) which is attributed to significan...
Spremljeno u:
| Izdano u: | Pulm Pharmacol Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier Ltd.
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7833560/ https://ncbi.nlm.nih.gov/pubmed/33259924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pupt.2020.101978 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|